Search This Blog

Thursday, October 31, 2019

AbbVie Q3 2019 Earnings Preview

AbbVie (NYSE:ABBV) is scheduled to announce Q3 earnings results on Friday, November 1st, before market open.
The consensus EPS Estimate is $2.30 (+7.5% Y/Y) and the consensus Revenue Estimate is $8.37B (+1.6% Y/Y).
Over the last 2 years, abbv has beaten EPS estimates 88% of the time and has beaten revenue estimates 75% of the time.
Over the last 3 months, EPS estimates have seen 8 upward revisions and 0 downward. Revenue estimates have seen 6 upward revisions and 2 downward.
Posted by at No comments:

Earnings before Friday’s open

ABBV, AMAG, IMGN, MD, MGLN
Posted by at No comments:

Ideaya Bio up 2% after hours on advancement of lead candidate

IDEAYA Biosciences (NASDAQ:IDYA) announces that, based on FDA feedback, it will initiate a 60-subject Phase 2 single-arm clinical trial evaluating lead candidate IDE196 as monotherapy for the treatment of metastatic uveal melanoma (MUM) this quarter.
The primary endpoint will be overall response rate (ORR).
If successful, it may support a U.S. marketing application under accelerated review status.
IDE196 is a protein kinase C inhibitor in-licensed from Novartis for GNAQ- or GNA11-mutation-positive solid tumors.
Posted by at No comments:

Eidos Therapeutics EPS of $0.18

Eidos Therapeutics (NASDAQ:EIDX): Q3 EPS of $0.18 may not be comparable to consensus of -$0.27.
Revenue of $26.69M beats by $24.61M.
Press Release
Posted by at No comments:

Select Medical EPS beats by $0.02, beats on revenue

Select Medical (NYSE:SEM): Q3 Non-GAAP EPS of $0.23 beats by $0.02; GAAP EPS of $0.24 beats by $0.03.
Revenue of $1.39B (+9.4% Y/Y) beats by $80M.
Shares +4.17%.
Press Release
Posted by at No comments:

AMN Healthcare Services EPS beats by $0.08, beats on revenue

AMN Healthcare Services (NYSE:AMN): Q3 Non-GAAP EPS of $0.81 beats by $0.08; GAAP EPS of $0.49 misses by $0.09.
Revenue of $567.6M (+7.7% Y/Y) beats by $4.91M.
Press Release
Posted by at No comments:

Bio-Rad Q3 sales up 3%, ytd cash flow up 65%

Bio-Rad Laboratories (NYSE:BIO) Q3 results:
Revenue: $560.6M (+2.8%); Life Sciences: $215.7M (+4.5%); Clinical Diagnostics: $341.8M (+2.4%).
Net loss: ($258.8M) (-196.1%); non-GAAP net income:$48.6M (+76.1%); loss/share: ($8.68) (-197.6%); non-GAAP EPS: $1.61 (+76.9%).
Cash flow ops (9 mo.): $298.1M (+65.2%).
GAAP results negatively impacted by a decline of $390.6M in the market value of securities held primary related to its investment in Sartorius AG.
2019 guidance: Revenue growth: 4.0 – 4.5%.
Previously: Bio-Rad Labs EPS beats by $0.20, misses on revenue (Oct. 31)
Posted by at No comments:
Subscribe to: Posts (Atom)